Your safety is our priority. We’re doing more than ever to help ensure your protection and well-being when you come see us for care. Learn more.

A Message to Our Community: Changes to our visitation policy are in effect until further notice.

Recent News

Irvine school nurses, staff learn Stop the Bleed techniques to respond in mass-casualty situation

Irvine school nurses and athletic trainers on Tuesday, Jan. 30, learned simple techniques that could save lives in a shooting or other ...

Read More

Families anticipate exciting community blessing of surgical center

A community is as strong as its hospital, and with recent investments into Covenant Health Plainview, it’s evident that to our friends ...

Read More

Severe Flu Season Tightens Its Grip on U.S.

Americans are being hit with one of the worst flu seasons in years, with misery now widespread across 46 states, health officials say. In ...

Read More

About St. Joseph Health

SJH provides a full range of care facilities including 16 acute care hospitals, home health agencies, hospice care, outpatient services, skilled nursing facilities, community clinics and physician groups. All of our hospital and home health entities are accredited by the Joint Commission. In our award-winning facilities, SJH maintains a "continuum of care," matched to the diverse needs of the urban centers, smaller cities and rural communities who depend on us every day.

Thomas A. Marsland, MD

4.9 out of 5 (86 Ratings)
  • Hematology
  • Hematology Oncology
  • Medical Oncology
    (Board Certified)
Additional Language Spoken
Medical Groups & Affiliations
  • St. Joseph Health Medical Group
  • St. Joseph Health Medical Network
St. Joseph Health Medical Group - Petaluma - Cancer Center
110 Lynch Creek Way
Suite A
Petaluma, CA 94954
Accepting New Patients

Primary Office

St. Joseph Health Medical Group - Petaluma - Cancer Center
110 Lynch Creek Way
Suite A
Petaluma, CA 94954
Get Directions
(707) 763-0600
(707) 765-1757
Mon - Fri: 8 a.m. - 5 p.m.

More Information

  • Meet The Doctor

    Specialties & Education

    Primary Specialties
    • Hematology
    • Hematology Oncology
    • Medical Oncology
      (Board Certified)
    Education & Training
    • Medical School
      Doctor of Medicine - 2005
    • College
      Bachelor of Arts - 1970
    • Training
      NIH Office of Human Subjects Research Course on the Protection of Human Research Subjects - 2000
    • Fellowship
      Hematology Fellowship - 1979
    • Fellowship
      Oncology Fellowship - 1977
    • Residency
      Residency (Medicine) - 1975
    • Internship
      Internship (Medicine) - 1974
  • Biography



    Dr. Marsland has over 30 years of experience in treating patients with hematologic and oncologic issues. He believes the doctor-patient relationship is a team with both parties involved in determining the best plan of care. He actively supports the St. Joseph Clinical Research Program. Dr. Marsland recently moved from Florida to Northern California (April 2017) with his wife to be near his family of three daughters and his new grandson. His hobbies include fine dining and good wine. The Sonoma/Napa County area are a great fit.


    I. Biomarker Analyses From a Randomized, Placebo-Controlled, Phase Illb Trial Comparing Bevacizumab With or Without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer, May' 13. Submission to Journal of Clinical Oncology.

    2. Atlas: Randomized, Double-Blind, Placebo-Controlled, Phase ll!B Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy With Bevacizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer, 2012. Johnson, B., Kabbinavar, F., Fehrenbacher, L., Hainsworth, J., Kasubhai, S., Kresse!, B., Lin, Chin-Yu., Marsland, T., Patel, T., Polikoff, J., Rubin, M., White, L., Chin-Hsin Yang, J., Bowden, C., Miller, V. Journal of Clinical Oncology 2012.

    3. Marsland, Lung Cancer Screening: A New Era Oncology, February 2012.

    4. Marsland, Reducing Cancer Costs & Improving Quality through Collaboration with payers, Journal of Oncology Practice, Sept. 2010.

    5. S.L. Wong, P. Mamgu, T. Chati, G. Dodd, G. Dorfman, C. Emg, T. Marsland. et al. American Society of Clinical Oncology, 2009 Clinical Epredesine Review of RFA of Hepatic met Journal of Clinical Oncology. 28:493-508, 2010.

    6. B. McAnemy, T. Marsland, K. King; News and Notes from 2009 CAC. Meeting Medical Necessity, off label News and Notes From the 2009 Carrier Advisory Committee Meeting: Medical Necessity, Off-Label Chemotherapy, and More, Journal of Oncology Practices; 301-304, Nov. 09.

    7, Matuzumab in second line treatment for patients with Stage III & IV NSCLC, J. Thorac One. '09.

    8. J.A. Bubis, I.A. Marsland, K.M, Justice, D. Edwards. Features of patients (pts) with metastatic breast cancer
    (MBC) and a circulating tumor cell count (CTCC) of 0. Accepted for poster discussions, San Antonio Breast Cancer Symposium, 2007. Abstract l 06.

    9. C.P. Belani, S. Ramalingam, M. Schreede, R. Steis, R. Guidice, T. Marsland, B. Butler. Phase II study of Cetuximab in combination with Carboplatin and Docetaxel for patients with advanced/Metastatic non small cell lung cancer (NSCLC). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol. 25, No. 18S (June 20 Supplement), 2007:764.

    10. Gray, J., Spigel, D., Hainsworth, J., Vazquez, E., Peyton, J., Raefsky, E., Malik, R., Marsland, T., Waples, J., Greco, F. Maintenance gefitnib (0) after chemo radiotherapy (CRT) in patients (pts) with unresectable stage IIIA/B non-small cell lung cancer (NSCLC): A Phase II trial of Minnie Pearl Cancer Research Network. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I, Vol. 24, No. 18S (June Supplement), 2006: 7188.

    11. Shipley, D., Hainsworth, J., Spigel, D., Gray, J., Barton, J., Switzer, A., Nicolau, M,, Marsland, T., Jospeh, G., Greco, F., Topotecan: Weekly Intravenous (IV) Schedule Similar to Standard 5-Day IV.Schedule as Second-Line Therapy for Relapsed Small Cell Lung Cancer (SCLC) -A Minnie Pearl Cancer Research Network Phase II Trial. Journal of Clinical Oncology 2006 ASCO Annual Meeting Proceedings Part I. Vol. 24, No. 18S (June 20 Supplement), 2006: 7083.

    12. Result ofa Phase II trial ofGencitabine in Patients with Non-Small Cell Lung Cancer and Performance Status of Two. Clinical Lung Cancer Trials, Volume 6 #4, 2005.

    13. I.A, Marsland, D.H. Garfield, M.M. Khan, R.M. Look, K.A. Boehm, L.A. Smar. Sequential vs Concurrent Paclitaxel and Carboplatin for treatment of advanced non-small cell lung cancer (ANSCLC) in elderly patients with poor performance status: results of two Phase II, multicenter trials. US Oncology Research Inc., 2004.

    14. Neubauer, M., Reynolds, C., Joppert, M., Whittaker, T,, Ahmad, Y., Ghaddar, H., Marsland, T., Asmar, L., US Oncology Research, Inc,, Houston, TX. Preliminary results of a phase II trial utilizing Gemcitabine in patients with advanced non-small cell lung cancer and a performance status 2. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceeding (Post Meeting Edition). Volume 22, No I 4S (July Supplement), 2004: 1721.

    I5. Sequential Verses Concurrent Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small Cell Lung Cancer in Elderly and Patients with Poor Performance Status. Result of our Phase II Trial Lung Cancer, June, 2004.

    16. Phase II Trial Utilizing Oemcitabine in Patients with Advanced Non-Small Cell Lung Cancer and a Performance Status 2, American Society of Clinical Oncology Abstracts, 2004, #7121 Poster Presentation.

    17. Liposomal Doxorubicin as a Single Agent Treatment of Low-Grade Non- Hodgkin's, Vol. 3 #4, 2003.

    18. Phase II Study of First-line Chemotherapy Using CT-2103 in Patients with NSCLC who are Less than or Equal to 70 years of Age or who have PS= 2. Abstract, 2002.

    19. Joppert, M., Garfield, D., Gregurich, M., Nemunaitis, J,, Marsland, T., Khandelwal, P., Asmar, L. US Oncology, Houston, TX. First-line Chemotherapy with Topotecan and Gemcitabine for Patients with Advanced Non-Small Cell Lung Cancer. American Society of Clinical Oncology Abstracts, 2002, #2671.

    20. Phase II Study if Sequential Chemo-Therapy followed by Maintenance Therapy with Oral Orzel in Patients with Stage IIIB & IV Non-Small Cell Lung Cancer. Abstract

    2I. U.S. Oncology Clinical Research the Role and Function of the Lung Committee. Abstract Second. World Conference on Clinical Research for Lung Cancer, 2002.

    22. Garbo, L., Marsland, T., Garfield, D., Khan, M., Asmar, L. US Oncology, Houston, TX., A phase II Study of Weekly Paclitaxel (Taxol®) In Stage IIIB, IV, or Relapsed After Local Therapy, Non-Small Cell Lung Cancer
    (NSCLC) Patients with a Performance Status of2 and/ or 70 Years of Age, with (Paraplatin®) Administered at Disease Progression. ASCO, 2001. Abstract #2821.

    23. Phase II Study of Weekly Taxol and Paraplatin in Stage IIIB & IV NSCLC in patients who are Less Than Equal to Age 70 and a Male with PS II. ASCO Abstract, 2001. #2819.

    24. Liposomal Doxorubicin as a Single Agent Treatment of Low-Grade Non-Hodgkin's. American Society Hematology Abstract, 2000.

    25. Estrogen Receptor Status and Response to Advance Breast Cancer. CANCER, 46;2919-2921, 1980.

    26. Estrogen Receptor Status and Response Chemotherapy. ASCO Abstracts, 1979.


    • Over twenty-six years clinical research experience, including industry and network trials.


    ASCO Self Evaluation Program

    • 2007 Lung Cancer Chapter
    • 2009 Presentation & Screening Chapter
    • 2011 Presentation & Screening Chapter
    • 2014 Preventions and Screening Chapter


    Veridex: Role of Circulation Tumor Cells

    • 2008 Houston, TX
    • 2009 Huntsville, AL
    • 2009 Huntsville, IN

    Cost of Healthcare with ION

    • 2008 Phoenix, AZ
    • 2009 Houston, TX

    Healthcare Economics (Con/era Group)

    • 2007 Charlotte, NC
    • 2008 Charlotte, NC
    • 2009 Princeton, NJ

    2012 Stress of Community Oncology Practices

    2012 Value Based Cancer Care Conferences

    2013 Value Based Cancer Care Conferences

    • American Board of Internal Medicine, Medicine, 1977 • American Board of Internal Medicine, Medicine 1979
  • 10-Jun-2020
    I have an ongoing problem & need to be monitored every few weeks - i.e., blood tests etc. *Dr. Marsland has been vigilant in this respect. He is an excellent MD.
    Attentive, concerned, knowledgeable,friendly, responsive. Good
    As always, I was treated with respect, felt listened to and the provider answered any and all questions I had.
    I felt cared about when i walked our of the office.
    I really like *Dr. Marsland as my doctor. I don't care for telemedicine visit because I wasn't given instructions how to get on the site and felt my session was hurried & cut short. I was disappointed. Also, I had to ask 3 times to have lab results sent to me.
    30 Total Comments Page 1 2 3 4 5 6   Next